Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals and CRISPR Therapeutics are researching the use of CRISPR/Cas9 gene editing to develop potential new treatments aimed at the underlying genetic causes of human disease, including transfusion-dependent β-thalassemia and severe sickle cell disease.